The Clinical Promise of Tissue Targeted Complement Therapeutics

Time: 10:40 am
day: Conference Day Two


  • Exploring Q32’s approach in utilizing tissue targeted therapies for complement mediated diseases
  • ADX-097’s ability to block complement activity whilst persevering natural immune responses
  • Exploring the benefits and the future promise of tissue targeted therapeutics in the complement industry.